EHA 2021 | Management of BTK class driven adverse events
Andrea Visentin, MD, PhD, University of Padua, Padova, Italy, gives an overview of the use of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia, in particular commenting on the management of adverse events associated with their use, such as atrial fibrillation, hypertension and bleeding. Dr Visentin reports on risk factors associated with atrial fibrillation for patients receiving ibrutinib, such as age and the presence of other cardiovascular diseases, and highlights the development of a risk assessment score for the prediction of risk of atrial fibrillation for patients receiving ibrutinib. Dr Visentin also talks on adverse events, in particular cardiovascular events, associated with second- and third-generation BTK inhibitors acalabrutinib and zanubrutinib. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrea Visentin, MD, PhD, has participated in consultancy work for Gilead, Italffarmaco, Janssen, and Takeda; is a member of the scientific boards of Janssen, Abbvie, CLS Behring; and has participated in speaker’s bureaus for Janssen, Abbvie, AstraZeneca.
